Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53
2009

How melanoma cells die from chemotherapy

Sample size: 11 publication 10 minutes Evidence: high

Author Information

Author(s): Naumann S C, Roos W P, Jöst E, Belohlavek C, Lennerz V, Schmidt C W, Christmann M, Kaina B

Primary Institution: University of Mainz

Hypothesis

How do temozolomide and fotemustine induce cell death in melanoma cells?

Conclusion

Temozolomide and fotemustine induce apoptosis in melanoma cells, with apoptosis being the dominant mode of cell death.

Supporting Evidence

  • Temozolomide induces apoptosis in melanoma cells using therapeutic doses.
  • Apoptosis was the dominant mode of cell death, with necrosis contributing 10-40%.
  • MGMT activity correlated with resistance to TMZ and fotemustine.
  • MGMT inactivation sensitized melanoma cells to drug-induced apoptosis.
  • DSB formation was associated with the apoptotic response to TMZ.

Takeaway

Melanoma cells can die from chemotherapy drugs, and they mostly die by a process called apoptosis, which is like a cell's way of committing 'cellular suicide'.

Methodology

The study involved treating 11 melanoma cell lines with temozolomide and fotemustine and measuring apoptosis and related cellular responses.

Potential Biases

Potential bias in the selection of cell lines and the interpretation of results based on specific cellular responses.

Limitations

The study focused on a limited number of melanoma cell lines and may not represent all melanoma types.

Participant Demographics

The study used human malignant melanoma cell lines derived from patients.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/sj.bjc.6604856

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication